Ke PAN
13Patents
2h-index
29Co-inventors
54Inventor score
Filing activity: Dec 21, 2000 → Mar 29, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7625945B2 | Andrographolide and analogues as inhibitors of TNFα and IL-1β expression | Human Necessities | 4 | Expired |
| US9758484B2 | Base addition salts of nitroxoline and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US10680145B2 | LED package structure and method for manufacturing same | Electricity | 1 | Active |
| US12152048B2 | Nitroxoline prodrug and use thereof | Chemistry; Metallurgy | 0 | Active |
| US8378364B2 | Multi-chip light emitting diode and method for fabricating the same | Electricity | 0 | Active |
| US11696933B2 | HLA-restricted VCX/Y peptides and T cell receptors and use thereof | Chemistry; Metallurgy | 0 | Active |
| US9263647B2 | Light emitting diode package structure and manufacturing method thereof | Electricity | 0 | Active |
| US12310960B2 | Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers | Chemistry; Metallurgy | 0 | Active |
| US12202877B2 | T cell receptors with mage-B2 specificity and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12171754B2 | Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers | Chemistry; Metallurgy | 0 | Active |
| US11324739B2 | Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers | Chemistry; Metallurgy | 0 | Active |
| US6583179B2 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | Chemistry; Metallurgy | 0 | Expired |
| US11185542B2 | Uses of dopamine beta-hydroxylase (DBH) inhibitors and serotonin receptor (5-HT) antagonists for the treatment of cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.